Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

E-GEOD-66493

ABSTRACT: Transcription profiling by array of human U87 cells treated with cytotoxic anticancer drug cisplatin or a ruthenium-based compound for 6 or 24 hours compared to untreated controls

PROVIDER: E-GEOD-66493 | ExpressionAtlas | 2015-03-16

REPOSITORIES: ExpressionAtlas

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	E-GEOD-66493-analysis-methods.tsv	Tabular
	E-GEOD-66493-atlasExperimentSummary.Rdata	Rdata
	E-GEOD-66493-configuration.xml	Xml
	E-GEOD-66493-percentile-ranks.tsv	Tabular
	E-GEOD-66493.condensed-sdrf.tsv	Tabular

Items per page:

1 - 5 of 107

Similar Datasets

RDC and cisplatin transcriptomes

Project description:Ruthenium based compound have developed for anticancer therapy Identification of the transcriptomes induced by either cisplatin or a ruthenium-based compound (RDC) that are both cytotoxic. Cells were treated with either cisplatin or RDC at their IC50 and for 6h or 24h. 15 samples are in the experiment. Each condition has been done in triplicates. Ct is control; R6 is RDC applied for 6h, R24 is RDC applied for 24h, C6 is ciplatin applied 6h and C24 is cisplatin applied for 24h. U87 cells were used.

2015-03-05 | E-GEOD-66493 | biostudies-arrayexpress

Evaluating microRNA profiles reveals discriminative responses following genotoxic or non-genotoxic carcinogen exposure in primary mouse hepatocytes [Exiqon]

Project description:The study investigated differential miRNA changes in primary mouse hepatocyte following 24 and 48 hours of exposure to aflatoxin B1, cisplatin, benzo(a)pyrene, 2,3,7,8-tetrachloordibenzo-p-dioxine, cyclosporin A or Wy-14,643 or their responsive solvent. Three (four for Wy-14,643) biological replicates per compound/solvent.

2015-05-18 | GSE57082 | GEO

Expression Profiles of PMH treated with 7M-BM-5M of the genotoxic compound cisplatin

Project description:The transcriptomic changes induced in primary mouse hepatocytes (C57BL/6 ) by 7M-BM-5M of cisplatin after treatment for 24 and 48h The study investigated differential gene expression in PMH mRNA following 24 and 48 hours of exposure to 7M-BM-5M of cisplatin and its solvent. Three biological replicates per compound/solvent. In total 12 arrays.

2013-12-05 | E-GEOD-38123 | biostudies-arrayexpress

Evaluating microRNA profiles reveals discriminative responses following genotoxic or non-genotoxic carcinogen exposure in primary mouse hepatocytes [Affymetrix]

Project description:The study investigated differential gene expression in primary mouse hepatocyte mRNA following 24 and 48 hours of exposure to aflatoxin B1, cisplatin, benzo(a)pyrene, 2,3,7,8-tetrachloordibenzo-p-dioxine, cyclosporin A or Wy-14,643 or their responsive solvent. Three (four for Wy-14,643) biological replicates per compound/solvent.

2015-05-18 | GSE57129 | GEO

Effects of SHetA2 on SiHa and C-33 A human cervical cancer cell lines

Project description:The objective was to identify how cervical cancer cells respond to treatment with the investigational new agent, Sulfur Heteroartoinoid A2 (SHetA2, NSC 726189) by identify proteins that are detected at significantly different levels in SHetA2-treated compared to untreated control cultures. Triplicate cultures of SiHa and C-33 A human cervical cancer cell lines were treated with 10 micromolar SHetA2 or the same volume of dimethylsulfoxide solvent (untreated controls) for 24 hours. Proteins were extracted from the cultures using M-PER (ThermoFisher).

2023-08-29 | PXD029537 | Pride

Gene expression and alternative splicing analysis of breast carcinoma cells treated by cisplatin.

Project description:MCF7 cells untreated and treated with cisplatin at 50µM for 24 hours.

2016-04-22 | E-MTAB-2663 | biostudies-arrayexpress

Expression Profiles of HepG2 cells treated with 7M-BM-5M of the genotoxic compound cisplatin

Project description:The transcriptomic changes induced in the human liver cell line HepG2 by 7M-BM-5M of cisplatin after treatment for 12, 24 and 48h The study investigated differential gene expression in HepG2 cell line mRNA following 12,24 and 48 hours of exposure to 7M-BM-5M of cisplatin and its solvent. Three biological replicates per compound/solvent. In total 18 arrays .

2013-12-05 | E-GEOD-38122 | biostudies-arrayexpress

RDC and cisplatin transcriptomes

2015-03-05 | GSE66493 | GEO

A new plant-derived compound, Hu-17, induces apoptosis and chemosensitization of ovarian cancer cells to platinum through activation of ROS-mediated JNK signaling

Project description:Platinum-based compounds exert their anti-neoplastic effect through direct binding to DNA, which blocks fundamental cellular process ultimately resulting in apoptotic cell death. However, many ovarian cancers become refractory to treatment with platinum-based compounds. To improve the existing therapies for ovarian cancer, we sought to identify potent, nontoxic and specific drug candidates that have anti-neoplastic effects towards cisplatin-sensitive and cisplatin-resistant ovarian cancer cells. Using a cell-based screening assay, we evaluated 56 compounds-derived from the Chinese medicinal plant, Phytolaccae, and one phytoaccagenin compound (Hu-17) was selected on the basis of its ability to dramatically decrease the viability of cisplatin-resistant SK-OV-3 cells.Using high-throughtput microarray system, we identified GO terms and pathway signatures enriched in Hu-17 and/or cisplatin treated SK-OV-3 cells.

2017-03-11 | GSE79098 | GEO

Cisplatin-Induced Changes in Proteomic Profiles of Ovarian Cancer Cell and Fibroblast Secretomes

Project description:Exogenous signals from drug-stressed cancer cells promote acquisition of a more aggressive phenotype of neighboring tumor cells. To identify extracellular signaling molecules that potentially contribute to the development of therapy resistance, we examined how cancer cell secretome changes in response to chemotherapy. We performed LC-MS/MS analysis of conditioned media (CM) from ovarian cancer cells SKOV3 before and 48 hours after cisplatin treatment. We identified 1,820 and 784 proteins in secretomes of cancer cells treated or untreated with cisplatin, respectively. Functional annotation of proteins which secretion increased after cisplatin showed that these proteins were mainly associated with cluster of spliceosome. To investigate whether secretion of spliceosomal proteins during induction of apoptosis is a specific property of tumor cells, we compared proteomes of CM from primary culture of normal human skin fibroblasts before and 48 hours after exposure to cisplatin (IC50). A LC-MS/MS analysis revealed that most of the proteins in the CM of fibroblasts and cancer cells under normal conditions overlap, while the secretomes after therapy demonstrate much more pronounced differences. GO and KEGG enrichment analysis revealed higher abundance of cell adhesion and extracellular matrix proteins in CM of fibroblasts before chemotherapy; while lysosomal proteins and growth factors, associated with wound healing were increased after cisplatin treatment. Spliceosomal proteins were only slightly present in fibroblast CM and did not show any changes in a response to chemotherapy. We suggest that the acquisition of ovarian cancer chemoresistance might be partially mediated by extracellular spliceosomal components.

2024-05-29 | PXD019096 | Pride

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data